Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.94
+0.03 (+0.23%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
October 24, 2022
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.
Via
InvestorPlace
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
October 19, 2022
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
Via
The Motley Fool
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
October 05, 2022
Via
Benzinga
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
September 21, 2022
Via
Benzinga
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
July 21, 2022
Via
Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
Via
Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
August 26, 2022
CNBC The Aviation Sector Is Slammed By Sky-High Rents
Via
Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
August 26, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
Peering Into Takeda Pharmaceutical's Recent Short Interest
August 08, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...
Via
Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...
Via
Benzinga
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
July 26, 2022
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
July 21, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
July 19, 2022
Upgrades
Via
Benzinga
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
July 18, 2022
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
July 05, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
June 08, 2022
Moderna tested a bivalent booster, which targets two Covid strains in one shot.
Via
Investor's Business Daily
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Current Report: Takeda Pharmaceutical
May 18, 2022
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.
Via
Talk Markets
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
April 21, 2022
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Via
InvestorPlace
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.